Tuesday is going to be a good day for Neurocrine Biosciences (NASDAQ:NBIX) and its shareholders. Strong data from the Phase IIb Kinect-2 study of NBI-98854 ('854) in tardive dyskinesia surprised the Street in a big way, and the shares are poised to jump as a potentially valuable drug suddenly looks much more viable than just a few months ago.
When it comes to the stock market and clinical trial data coming out of biotechs, the reactions often remind me of a cat chasing a laser pointer. Keep that in mind when contemplating the ultimate odds of approval and the challenges in designing a Phase III study that will not only cast the drug in the best light, but...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|